Dr. Gabriel Pineda

Gabriel Pineda, Ph.D., MS, CLS, MLS(ASCP), received his PhD in Genetics and Development from UT Southwestern Medical Center at Dallas, studying ubiquitin mediated regulation of NF-KappB signaling. Dr. Pineda received his MS in Molecular Biology from UTEP and his BS in Microbiology from the University of Texas at Austin. Dr. Pineda is a member of the American Society of Microbiology (ASM) and is also a CA, licensed clinical laboratory scientist (CLS). Prior to joining National University, Dr. Pineda served as a Senior Scientist at the University of California, San Diego where he led the efforts to identify small molecules inhibitors of the RNA deaminase ADAR1. Dr. Pineda completed two postdoctoral fellowships at UCSD in cancer therapeutics and cancer stem cell biology. His peer-reviewed publications include articles in the journal Scientific Reports, Cell Stem Cell, Journal of Translational Medicine, and Nature Communications.

Publications

• (July 01, 2020). Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions.. Blood Cancer Discov..


• (December 07, 2017). Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.. Nature Commun..


• (n.d.). Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.. Int J Mol Sci..


• (n.d.). Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation.. Cancer Cell.


• (n.d.). Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution.. Cell Reports.


• (n.d.). Reversal of malignant ADAR1 splice isoform switching with Rebecsinib.. Cell Stem Cell.